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Abstract
Background: Subacute Sclerosing Panencephalitis (SSPE) is so rare in developed countries with
measles immunization programs that national active surveillance is now needed to capture sufficient
number of cases for meaningful analysis of data. Through the Canadian Paediatric Surveillance
Program (CPSP), the SSPE study was able to document a national incidence and determine the
epidemiology of affected Canadian children.
Methods:  Between 1997 and 2000, the CPSP surveyed monthly 1978 to 2294 Canadian
pediatricians and sub-specialists for SSPE cases. The response rate varied from 82–86% over those
years.
Results: Altogether, four SSPE cases were reported to the CPSP: one case before, two during and
one after the study period. The incidence of SSPE in Canadian children was 0.06/million children/
year. Of the four cases, diagnosed between ages four and 17 years, three children had measles
infection in infancy. All children showed a progressive course of dementia, loss of motor skills and
epilepsy. Two children were treated with isoprinosine and intraventricular interferon but died in
less than three years from disease onset. One child did not have any treatment and died after seven
years of illness. One child received intraventricular ribavirin and remains alive, but markedly
impaired, nine years following diagnosis.
Conclusion: The CPSP has demonstrated that Canadian paediatricians and paediatric neurologists
may encounter cases of SSPE. This report highlights the clinical course of affected Canadian children
and provides a review of the disease and its management.
Background
Measles infection and its associated complications have
become uncommon in Canada since widespread immu-
nization was implemented in 1963. One such complica-
tion, Subacute Sclerosing Panencephalitis (SSPE), is a
devastating, progressive, central nervous system destruc-
tive process caused by mutant measles virus infection of
neurons. Typically, affected persons have a history of mea-
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sles infection in infancy period [1]. Years later the clinical
features of SSPE develop. The disease is characterized by
dementia, deterioration of motor function and epilepsy.
Although decline may be punctuated by periods of clini-
cal plateau, a gradual progressive course leading to death
is invariable.
Because of the uncommon nature of SSPE in Canada the
epidemiologic and clinical experience with the disease is
limited. The Canadian Paediatric Surveillance Program
(CPSP) initiated a study in 1997 [2] to determine a
national incidence and the epidemiological features of
this disorder, including any potential contribution that a
vaccine-strain virus might have in to the etiology of this
disease.
The purpose of this article is to present the four cases that
were reported to the CPSP and review the literature with a
focus on the clinical issues and management of the dis-
ease.
Methods
The Canadian Paediatric Surveillance Program is a
national program developed to conduct population-
based identification of rare diseases through active sur-
veillance of Canadian pediatricians and paediatric sub-
specialists. The SSPE proposal was approved by the CPSP
Steering Committee and funded by Health Canada. All
Canadian pediatricians were provided with an SSPE case
definition (Table 1) and protocol [2] on initiation of the
surveillance study. Between January 1997 and December
2000, the CPSP sent an initial report form monthly to an
average of 2157 pediatricians and pediatric neurologists
with a query as to whether or not a new case of SSPE had
been encountered. If a case was identified a follow-up epi-
demiological questionnaire focusing on the demographic
data, history of illness and diagnostic tests was completed
by the reporting pediatrician. Duplicate cases were elimi-
nated. Only non-nominal data were collected, namely sex
and birth date, to maintain patient confidentiality.
Updates on number of reported cases were provided quar-
terly. The response rate ranged between 82–86% during
this time period. Given the severity of this condition, the
awareness created by the widespread distribution of edu-
cational material and the high response rate, one can
assume that the population under surveillance approxi-
mates the Canadian child population.
The information from the case report form was supple-
mented by clinical information from the original report-
ing pediatricians when possible. In the third clinical
report further details of the brain biopsy unfortunately
could not be obtained. Searches of Medline using the
OVID platform were conducted for treatment trials and
other clinical descriptions of affected pediatric popula-
tions.
Results
Clinical report 1
A 6-year-old girl of Filipino origin presented to the emer-
gency department in July 2001 with an eight-day history
of progressive weakness and abnormal movements. The
movements consisted of sudden head drops described by
parents as brief sleeping episodes and new onset of drop-
ping objects. She had also been noted to have a fine
tremor, fidgetiness, unsteady gait and frequent falls. Her
behavior was described as more irritable and emotionally
labile. Parents had noted a longer history of difficulty
understanding her speech, decreased recall of the names
of common objects, and requiring help to feed/use wash-
room. Past medical history revealed measles infection at
four months of age in the Philippines and that she
received standard Canadian immunizations upon immi-
gration at age two years.
On exam the child was pleasant and cooperative but was
not able to comply with two step commands. She did not
know her parent's first names, her phone number or
address. Cranial nerve, motor and sensory exam were all
normal. A fine intention tremor was evident in the upper
extremities. Every 5–10 seconds the child would have a
brief myoclonic movement of the whole body with head
flexion, eye closure and arm extension. She would often
fall during these myoclonic jerks but otherwise her gait
and balance appeared intact.
A video EEG confirmed the presence of high amplitude
periodic discharges [See Additional file 1] associated with
head drops. Investigations from the CSF were normal
except for oligoclonal banding and markedly elevated
measles virus IgG at 7100 mIU/ml consistent with the
diagnosis of SSPE. The diagnosis was confirmed within 3
weeks of initial presentation. A Brief Assessment Examina-
tion showed a score of 18 with 60 being the greatest
impairment (see below). An initial MRI was normal but
within three months a second MRI showed diffuse cere-
Table 1: Case Definition.
Definite Case
A. High titres of serum antibodies against measles virus and the 
presence of oligoclonal measles virus antibodies in CSF (Serum: CSF 
measles antibody ratio indicative of intrathecal antibody production).
And/or
B. Measles virus antigen detected in brain tissue by biopsy or at 
autopsy
Suspect Case
A. Typical clinical history: usually insidious onset of mental 
deterioration, followed (usually within a few months) by motor 
dysfunction, final progressive decerebration and untimely death
And
B. Typical EEG changesBMC Pediatrics 2005, 5:47 http://www.biomedcentral.com/1471-2431/5/47
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bral atrophy and a hyperintense lesion in the left temporal
lobe on T2 weighted images.
Treatment with high dose valproic acid and clonazepam
significantly improved the myoclonic seizures. Isoprinos-
ine was started immediately (100 mg/kg divided qid)
upon diagnosis but by one month later on admission for
insertion of the Ommaya reservoir and initiation of intra-
ventricular interferon-alpha (IFN-α) 2B her clinical state
had deteriorated. She was minimally responsive, no
longer vocalizing needs, had few purposeful movements
and poor head control. Despite this the treatment with
intraventricular IFN-α 2B was initiated at 1 million units
per day for 2 weeks, then weekly for six weeks, then every
other week for three months. No improvement in the
child's function occurred but no further deterioration was
noted. Other symptomatic treatments included g-tube
feeding, physiotherapy, glycopyrrolate to decrease oral
secretions. Mild thrombocytopenia and fevers with injec-
tions occurred but did not interfere with the treatment.
Due to a lack of clinical improvement, the interferon and
isoprinosine were discontinued after five and eighteen
months respectively.
Gradually the clinical picture progressed to diffuse rigid-
ity, brisk reflexes with clonus and multifocal myoclonus.
The child remained stable albeit in a state of minimal
responsiveness, with no communication or purposeful
movement until she died of a respiratory illness in March
2004, two and a half years after her diagnosis. No autopsy
was performed.
Clinical report 2
A 14-year-old boy born in Canada presented in late 1997,
at seven years of age, with staring spells, diagnosed as
absence epilepsy but over the next year developed atonic
seizures consisting of head drops, myoclonic seizures, and
then generalized tonic clonic seizures lasting approxi-
mately two minutes. Approximately one year after the
onset of his seizures he was losing skills such as tying his
shoelaces, and dressing himself and needed to be trans-
ferred out of a regular classroom.
His past medical history was significant for being born at
26 weeks gestation, and having mild respiratory distress
syndrome and then bronchopulmonary dysplasia. No
intracranial pathology was detected clinically or by head
ultrasound at that time. Since infancy there had been no
significant illnesses. There was no history of measles dis-
ease or contact in the first year of life. His immunization
record confirmed that all immunizations had been appro-
priately given including MMR in June 1992 at the age of
21 months and measles booster at 6 years of age.
Clinical examination revealed a head circumference of
53.7 cm (80th percentile). Cranial nerves were intact
including a normal fundoscopic exam. There was mild
hypotonia and normal power. Deep tendon reflexes were
generally brisk. Plantars were upgoing bilaterally.
Initial EEG demonstrated generalized 3 Hz spike wave
and polyspike and wave. A subsequent EEG five months
later showed marked abnormality with no normal rhyth-
micity and intermittent projected activity consisting of
high voltage delta and multifocal sharp waves in bursts
with attenuation of faster frequencies. These occurred at
times in a quasi periodic fashion approximately every five
seconds throughout the recording. In addition there were
multiple independent spikes and sharp waves. MRI
showed high signal in the periventricular white matter.
CBC, electrolytes, calcium, magnesium, liver function
tests, renal function tests, lactate, ammonia, creatine
kinase, plasma and urine amino acids, urine organic
acids, very long chain fatty acids, mucopolysaccharides
and oligosaccharides were all normal. Skin biopsy did not
show any inclusions on electron microscopy. Toxicology
screen normal. The major findings of note were in the cer-
ebrospinal fluid obtained in April 1999. Nucleated cell
count was 3 × 106/L and protein was 662 mg/L. CSF IgG
was 212 mg/L (nr 0–64) and CSF IgG/albumin ratio was
1.91 (nr 00-0.23). CSF measles titre was 2460 mIU/ml (nr
= 0). The diagnosis of subacute sclerosing panencephalitis
was made in April 1999. Given the lack of infant measles
infection, the history of prematurity and the atypical EEG
the diagnosis of SSPE was only arrived at after extensive
investigation into all neurodegenerative disease.
He was not treated with specific antiviral therapy. At the
time of his most recent visit, age 131/2 years, he was hav-
ing seizures every three weeks consisting of clonic move-
ments of the face and both arms lasting up to one minute.
He was using a wheelchair outside the home. On exami-
nation he remained very interactive socially and appropri-
ately verbally responsive to simple questions. He was
somewhat disinhibited. Cranial nerves were intact. Fun-
doscopic exam showed peripheral diffuse retinal atrophy
consistent with previous retinal choroiditis. There was a
mild right dystonic hemiparesis superimposed on a mod-
erate spastic diplegia. In addition there was marked cere-
bellar tremor in the upper limbs, significant dysmetria
and gait ataxia. This child recently died due to respiratory
illness and no autopsy was performed.
Clinical report 3
A 14 year old girl born in Canada presented in March
1996 at six years of age with a history of a respiratory
infection two months prior to her presentation. From that
time she had been lethargic, slow to complete school
assignments and unable to understand simple requestsBMC Pediatrics 2005, 5:47 http://www.biomedcentral.com/1471-2431/5/47
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around activities of daily living. Her sleep pattern had also
become disturbed. One month later she began to have
drop attacks. The only other symptom of note was head-
ache for five days. Her chest x-ray demonstrated bron-
chopneumonia and she was treated Erythromycin at her
local hospital. A CT scan and EEG were reported to be nor-
mal
Her past medical history revealed that she was the product
of a normal delivery at 38 weeks, weighing 2.5 kg. At 13
months of age she contracted pneumococcal meningitis
but had a complete recovery from this. Because of her
meningitis, she had not received her MMR immunization.
At 14 months of age she contracted measles. Subsequently
she had recovered from her illnesses and her development
had been entirely normal.
Clinical examination revealed a lethargic but cooperative
girl. There was bilateral papilloedema and focal chori-
oretinitis. Cranial nerves were otherwise intact. The motor
examination was entirely normal. She had a mildly asym-
metric gait but there was no ataxia.
EEG showed multiple independent spikes and back-
ground slowing. Her MRI was normal. Lumbar puncture
revealed a pressure of 36 mmHg but in March 1996 the
CSF glucose (3.7 mmol/L) protein (195 mg/L) leukocyte
count (3 × 10-6/L) were normal. CSF measles PCR was
negative. Initial treatment included clonazepam, val-
proate and dexamethasone. Over the next two weeks she
deteriorated dramatically to the point where she would
give only one word answers, demonstrated marked ataxia
and significant decline in cognition. Myoclonic seizures
were evident. A further EEG revealed periodic complexes.
Plasma measles IgG by enzyme immunoassay was 4.34
(EIA units cutoff value < 0.7). CSF measles PCR was nega-
tive. No virus was cultured but the CSF measles IgG by
enzyme immunoassay was 3.58 EIA units (nr = 0).
Within one month of her presentation she had deterio-
rated to the point where there were periods of time when
she appeared not to be aware of her surroundings and was
ataxic to the point where she needed to be fully supported
when walking. She had only occasional words and contin-
uing myoclonia. She was treated with intravenous ribavi-
rin 100 mg/kg/day as a q 6 h regimen and ribavirin levels
were measured both in the plasma and CSF. It was felt that
the levels obtained in the CSF were not adequate to
inhibit viral replication, and therefore, it was decided to
give intraventricular ribavirin using an Ommaya reservoir.
The dose was gradually increased over ten days from 1
mg/kg/day to 10 mg/kg/day. This treatment did not pro-
duce any reversal in her clinical symptoms and signs and
was discontinued.
At the time of her last visit, age 13 years, the major issues
were that she was sleeping through most of the day, being
awake for a total of 4–6 hours per day in periods of half to
one hour. Her seizures had continued to be a major prob-
lem but had improved significantly on a small dose of
topiramate. Clinical examination revealed no interaction
and evidence of a severe spastic quadriparesis. There was
evidence of decerebrate posturing.
Clinical report 4
A 16 year old boy born and raised in Iraq until 6 years of
age, presented with a diffuse red rash on his upper extrem-
ities and trunk in September 1998, followed by a rapid
change in behavior over the next three months. He was
described as having memory problems, social isolation
and poor concentration. He then developed myoclonic
jerks of the extremities and was admitted for investigation
four months after his rash.
At one year of age the child had suffered a measles-like ill-
ness. Family claimed he had received immunizations
upon entering Canada but this was not confirmed.
On examination the child manifested significant mental
status changes. He was disoriented in all spheres and una-
ble to read, write or speak. Formal motor and sensory
exams were not able to be performed given his mental sta-
tus. There were almost continuous myoclonic seizures.
EEG demonstrated quasi-periodic bursts of high voltage
slow wave activity at intervals of 4–9 seconds which corre-
lated with myoclonic jerks seen in the patient. The EEG
background was otherwise normal. MRI showed focal sig-
nal abnormalities in the left occipital lobe without
enhancement. Serum and CSF showed elevated levels of
measles IgG (exact values not available) in January 1999.
A brain biopsy did not clearly delineate findings of SSPE.
The child was treated with isoprinosine 1 gram tid from
diagnosis until death. He also received, via an Ommaya
reservoir, intra-venticular IFN-α 1 million units twice a
week for two weeks, then three times a week for three
weeks and then once a week for a month and then it was
discontinued. Seizures were treated with valproic acid 750
mg tid.
He was transferred to a pediatric rehabilitation centre after
his diagnosis and in October 1999 he was brought back to
hospital with generalized body rigidity, fever and agita-
tion. He developed adult respiratory distress syndrome
and renal failure due to rhabdomyolysis. Creatine kinase
levels were 47,000. The specific cause for his sudden dete-
rioration was not clear with infection, malignant hyper-
thermia or dystonic spasm directly related to SSPEBMC Pediatrics 2005, 5:47 http://www.biomedcentral.com/1471-2431/5/47
Page 5 of 10
(page number not for citation purposes)
considered. He died within two weeks of re-admission
and no autopsy was performed.
Discussion
The following sections will focus on a review of the epide-
miologic, clinical and treatment issues of SSPE. For the
interested reader a discussion of the pathophysiology of
this unusual infection is dealt with in several important
references but will not be discussed in this article (3–8).
Epidemiology
The four cases identified in this investigation highlight the
rare nature of SSPE in Canada. Of the four cases presented
only two were actually incident cases during the surveil-
lance period with one case each being diagnosed just
before and just after the monitoring. So, if the sampled
time period is typical, then the incidence is 0.5 cases per
year in Canadian children. Using Canadian Census data
for the endpoint of the surveillance period (2001) for the
pediatric population (under 19 years) then the incidence
would be 0.06 per million children per year (2 cases per
7.778 million children per 4 years). This incidence is con-
sistent with other post immunization countries [9]. In
Canada the annual number of cases of measles infection,
which is a reportable disease, in the period just preceding
the CPSP study (1990–1997) ranged from 204–6178 with
a median of 808. Following the introduction of a 2-dose
program and catch-up campaigns in 1997 the total
number of measles infections have been 259 over 4 years
(1998–2001) with 199 of these cases linked to a series of
outbreaks in 2000 [10] Two of the children in this study
contracted measles infection in other countries. In the
other two children the risk of SSPE related to measles
cases in Canada can be estimated based on the probable
time of their infection. Both children were born in 1990
with case #3 having measles infection in 1991. Assuming
the other child's exposure to be in the first 2 years of life
then estimate of SSPE can be made using these two cases
and the total number of Canadian measles cases from
1990–1991. There were 1000 cases of measles in 1990
and a large out break in Canada in 1991 with 6178 cases
[10], which translate into a risk of 2 cases per 7178 mea-
sles cases or 278 cases/million measles infection which is
consistent with other estimates in developed countries
(See Table 2.), but is higher than formerly reported [1].
Several countries have reported on the epidemiology of
SSPE through different methods of surveillance and these
are presented in Table 2. Estimates of the risk of SSPE
related to total population and the number of measles
infections are included in the table. In some cases these
estimates are derived from the total number of measles
cases in a specific region during a specific epidemic. We
have converted these figures to show the cases of SSPE per
million cases of measles infection and note a large range
from 8.5–1449 cases/million.
Table 2: Epidemiologic Studies of SSPE
Country and years (reference) Study method Incidence and immunization 
status of population
SSPE cases per Measles cases 
in general population in 
relevant time period (cases of 
SSPE/million cases of 
measles)
State of California, USA, 1998–
2003 [41]
Passive surveillance. 5 cases over 5.5 years. Active 
immunization.
4 cases related to a 2 year 
epidemic of 16,400 cases of 
measles in California. (243 cases/
million)
Bulagria 1978–2002 [42],[43] University hospital sample. 40 cases over 25 years. No 
population figures given. Active 
immunization.
Not available.
South China 1988–2002 [44] Physician survey and hospital 
record diagnostic code search.
5.5/million children. Active 
immunization.
At least 6 cases related to a 
epidemic of 4140 cases in one 
year. (1449 cases/million)
England and Wales 1990–2002 
[45]
Passive surveillance. 47 cases (not all pediatric). No 
incidence figures given. Active 
immunization.
1 case per 25,000 measles 
infections. 1 case per 5,500 if 
measles infection in first year. (40–
200 cases/million)
Japan 1977–1999 [46] Unclear from abstract. 0.58/million population Not available.
Papua New Guinea 1997–1999 
[47]
Single hospital sample. 98/million child population. Active 
immunization but poor coverage.
Not available.
Australia 1995–1998 [48] Active surveillance. 0.02/100,000 children per year Not available.
Brazil 1990–1996 [49] Survey of child neurologists with 
84% response rate.
48 cases over 7 years Not available.
USA 1980 [1] Passive surveillance. 0.06/million population under 20 
years
8.5 cases of SSPE/million cases of 
measles infection for 1960–1974.BMC Pediatrics 2005, 5:47 http://www.biomedcentral.com/1471-2431/5/47
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Only one of the cases reported in this study actually
occurred in a child of Canadian origin whose infection
pathogenesis was as a result of the standard exposures
usually encountered by Canadian children. The other
three cases were more typical in their pathogenesis, occur-
ring following a clinically obvious measles infection in
infancy. As in most described SSPE cases the measles
infection in the latter three patients happened before age
two years [11]. In all of the literature examined for this
paper there is no evidence that vaccine virus strains were
the cause of any case of SSPE even when no obvious clin-
ical measles infection occurred.
Clinical features
The typical presentation is that of a child presenting with
cognitive deterioration combined with ataxia and/or
myoclonus. Families may comment on head drops or
events which may be mistaken for brief episodes of sleep
or common childhood falls. The myoclonic events are fre-
quently whole body spasms that occur in a periodic
nature every 4–10 seconds. The brief body stiffening is
often associated with eyelid closure and abduction of the
arms but, can be subtle with a sudden head drop or buckle
of the knees. The periodic myoclonus is typically quite
disabling even when patients are still functioning well
intellectually. Other seizure types can be encountered, as
seen in case 2, but the periodic myoclonic event is charac-
teristic of the disorder. More uncommon presenting fea-
tures have been described such as: tremor, dystonia,
headache and hemiparkinsonism [12], chorioretinitis
[13], hallucinations [14]. The history of a measles infec-
tion may be difficult to determine, as in our first case,
either due to a mild course, or to cultural or language dif-
ferences if adequate translational services are not used.
The clinical features have been divided into four stages
[15]. These stages are shown in Table 3. Progression
through these stages is variable with a well recognized ful-
Table 3: Clinical outcome measures used in SSPE.
Measure Descriptor
Jabbour Stages [15]
Stage IA Behavioral, cognitive and personality change only.
Stage IB Myoclonic Spasms: focal and not periodic.
Stage IIA Further mental deterioration. Myoclonic spasms: periodic, generalized, 
frequently causing drop spells precluding ambulation
Stage IIB Apraxias, agnosias, language difficulties. Motor signs: spasticity, ataxia. 
Ambulation with assistance only.
Stage IIIA Speaking less, visual difficulties. Sits up. Myoclonic spasms frequent 
(every 3–5 seconds). May have seizures.
Stage IIIB No spontaneous speech, poor comprehension, blind. Myoclonic spasms. 
Bedridden, dysphagia. EEG background delta. Other abnormal 
movements: chorea, ballismus.
Stage IV No myoclonic spasms. EEG low voltage with no periodic slow wave 
complexes. Patient in a vegetative state.
Neurologic Disability Index (NDI) [23]
Behavioral/Mental Irritability, Personality, Withdrawal, Intelligence and Higher cortical 
function
Myoclonia/Seizures Location, Repetition, Frequency, Seizures (major), Synchrony
Motor/Sensory Reflexes and tone, Strength and bulk, Abnormal postures and 
incoordination, Movements, Sensory modalities
Vegetative/Systemic Vision, Hearing, Verbalizations, Autonomic, Nutritional
For each characteristic a score is given from 0 to 4 indicating 'No abnormality' to 'Profound abnormality'. Total Score is 80 and converted to a 
percentage. A higher score indicates greater impairment.
Brief Assessment Examination (BAE). [22]
Alertness No response = 8. Minimum general response = 6, Specific response 
(35% level) = 4. Specific response (70% level) = 2. Normal = 0.
Receptive Speech/Language and Cognitive Follows commands 0–3. Points at objects 0–3. Points at colours 0–3. 
Points at shapes 0–3.
Visual Digit Span Zero digits = 8. One digit = 6. Two digits = 4. Three digits = 2. Four 
digits = 0.
Speech No response= 8. Severe dysarthria = 6. Moderate dysarthria = 4. Mild 
dysarthria = 2. Normal = 0.
Mathematics No skills = 8. Counts to five = 6. Counts to ten = 4. Single digit addition 
= 2. Single digit subtraction = 0.
Pictorial Memory Zero objects = 8. One objects = 6. Two objects = 4. Three objects = 2. 
Four objects = 0.
Total Score is out of 60 with greater scores reflecting greater impairment. Modifications are outlined for children less than 6 years of age.BMC Pediatrics 2005, 5:47 http://www.biomedcentral.com/1471-2431/5/47
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minant or acute course where the patient develops at least
66% neurologic disability (as measured by the NDI, see
Table 3) in the first 3 months or death within six months
[16]. In contrast protracted survival, in the late stages of
the disease usually in a vegetative state, has been
described both in natural history and treated case reports.
The most characteristic aspect of the myoclonic events is
their 4–10 second periodic nature. The episodes are asso-
ciated with a high amplitude bi or triphasic spike or slow
wave discharge on EEG with a normal background ini-
tially. With time the background rhythm deteriorates and
the myoclonic discharges become less evident.
CT scans are rarely helpful, but may show low density
changes in affected areas. MRI abnormalities are most
commonly seen in the white matter with high signal
intensity in T2 and FLAIR images [17]. One study focusing
solely on the MRI findings in 26 patients with SSPE
showed that normal scans were uncommon, seen in only
3 patients, all in the early stages of disease [18]. Isolated
cortical signal change was equally uncommon in this
series with only one child showing this finding. Most of
the high signal lesions were in subcortical white matter or
periventricular white matter, or both. Lesions in the cor-
pus callosum were noted in only six children but never as
an isolated finding. Five patients demonstrated either
mass effects or contrast enhancement in association with
lesions. Diffusion weighted change on MRI may be asso-
ciated with the white matter lesions [19] but there is little
evidence currently. Deep gray matter hyperintensities
have been reported but are less common [19,20]. Progres-
sive cerebral atrophy can be demonstrated on follow-up
imaging. Uncommonly, large 'mass-like' cortical and sub-
cortical lesions have been reported on MRI [12].
MRI spectroscopy has been carried out in six patients with
SSPE and compared to healthy controls and no differ-
ences are noted in the early stages of disease. Later in the
clinical course decreased N-acetylaspartate and increased
choline and myo-inositol peaks did distinguish the
affected children, reflecting neuronal loss, glial prolifera-
tion and inflammation respectively [21].
Outcome measures
Efforts have been made to use traditional psychology
assessments (eg. Bayley Scales) to monitor responses to
treatment in SSPE but the degree of impairment and the
fact that these measures were developed for developing
infants not dementing children with physical limitations
has led to difficulties in administration and scoring [22].
In response to these problems two measures have been
developed and used in the setting of SSPE to follow
change and assess response to treatment (Table 3).
The first measure, the Neurologic Disability Index (NDI)
[23], may be the most sensitive to change but is poorly
described and complicated to apply. The second measure,
the Brief Assessment Examination (BAE), has been devel-
oped specifically for SSPE [22]. This measure has been
described in detail so that it is easily reproduced. Further-
more, the BAE is weakly correlated with the NDI but more
importantly highly correlated with disease stage. Data on
the test-retest reliability over four time intervals was
reported in the original description but the rapid clinical
deterioration of most children in the sample made only
short interval correlations fall into the excellent range
[22].
Treatment
The pharmacologic management of SSPE can be divided
into disease modifying agents and symptomatic therapies.
The latter is largely directed at seizure control and all the
evidence is empirically based. Many different anticonvul-
sants have been used and one report of successful treat-
ment of myoclonic movements with trihexyphenidil is on
record [14]. The disease modifying agents are outlined in
a table found in additional file 2 with sections divided by
level of evidence rather than by drug as many combina-
tion therapies have been evaluated.
Two medications, isoprinosine (or inosiplex) and inter-
feron, have received the most attention. The first agent is
not an antiviral agent but rather an immune modulating
substance that facilitates lymphocyte immune function
once triggered by a viral antigen [24]. In the setting of viral
infections a general immunodepressive state is encoun-
tered, both in animal models and humans, which isopri-
nosine has been shown to improve by promoting
lymphocyte proliferation and the production of immu-
noglobulin and lymphokines. Interferon has received
attention because it activates natural killer cells and
directly inhibits viral replication [25]. Typically in SSPE
IFN-α is administered intraventricularly through an
Ommaya reservoir, but the use of beta-interferon subcuta-
neously has been reported in a case series of seven patients
with clinical improvement or stabilization noted in three
[26].
Until recently no randomized controlled trials of isopri-
nosine and interferon had been conducted. In response to
this the International Consortium on SSPE conducted a
single blinded, randomized controlled trial enrolling
patients from 1996 until 2000 [27]. The experimental
group received isoprinosine and intra-ventricular IFN-α
and the control group was treated with isoprinosine alone
given that a placebo control was felt unethical. Survival
analysis showed no significant difference in groups over
the first 6 months after which the dropout rate was so high
no statistical analysis could be completed. No significantBMC Pediatrics 2005, 5:47 http://www.biomedcentral.com/1471-2431/5/47
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difference was noted on the BAE or the NDI over two years
follow-up. Despite 121 subjects being randomized only
about half this number was used in any of the outcome
evaluations primarily due to lack of initial baseline assess-
ments but also due to 19 protocol violations. No inten-
tion to treat analysis was presented.
In a case control study Anlar et al. (1997) [28] compared
the clinical outcome of 22 children treated with isoprino-
sine and intra-ventricular IFN-α with 35 children treated
with isoprinosine only. IFN was given as 100,000 units/
m2 increasing to 1 million units/m2 per day for 5 days/
week for six weeks at a time and repeated at 2–6 month
intervals. Little data was given for the control group and it
is not clear why they did not receive IFN-α given they were
diagnosed during the same period. Half of the IFN group
improved initially and until approximately eight years fol-
lowing diagnosis these children enjoyed a better survival
profile. Although many case reports describe clinical ben-
efits for children treated with IFN there are several case
reports that report poor outcomes [29,30]. CSF measles
antibody titres may fall with treatment [31] however it is
not clear that this is always related to clinical improve-
ment [26,29,32,33].
Although there does not appear to be a substantial differ-
ence to clinical outcome with the addition of IFN to iso-
prinosine compared to natural history data, the number
of patients who stabilize on treatment suggests that isopri-
nosine at least is helpful. These conclusions are supported
by observational research. The effectiveness of isoprinos-
ine was demonstrated in a Japanese multi-site retrospec-
tive study of 89 children treated with isoprinosine and 62
untreated [34]. The dosage used ranged from 26–190 mg/
kg/day (mean 63 mg/kg/day) and the duration was as
long as five years and one month. Similar initial disease
characteristics were noted between the groups but the
children who received isoprinosine were three times more
likely to have been additionally treated with IFN, whereas
the 'untreated' group received corticosteroids more fre-
quently, reflecting a change in clinical practice during the
study period. Kaplan Meier curves demonstrated a one
and five year survival of 97.6% and 86.3% in the treated
group compared to 75.4% and 51.2% in the untreated
group. These results were found to be statistically signifi-
cant. Subgroup analysis did demonstrate an apparent det-
rimental effect of corticosteroids and benefit of IFN on
survival. Other measures of clinical course such as Jab-
bour and Freeman stages and physician judgment of out-
come also favoured isoprinosine use. Seventeen children
had 27 side effects including hyperuricemia, nausea/vom-
iting, changes in liver enzymes and drop in blood cell
counts, but none required discontinuation of the medica-
tion. Two other observational studies found similar
results [35,36].
Other immunomodulating or antiviral medications have
been examined in SSPE. A randomized trial of cimetidine
(20 mg/kg/day) was conducted in 14 children (rand-
omized 1:1) who refused, did not tolerate or were unable
to obtain isoprinosine [37]. Although not statistically sig-
nificant the treatment group appeared to have less deteri-
oration on the NDI after two months than placebo
controls. Another randomized trial used immune stimula-
tors in combination with isoprinosine. Children were ran-
domized to either thymus extract in addition to
isoprinosine, or an IFN stimulator plus isoprinosine, or
isoprinosine alone. The three groups were compared and
it was felt by the authors that the combination treatment
group had better outcome compared isoprinosine alone
but no differences in outcome reached statistical signifi-
cance [50]. Ribavirin has been used as adjunct therapy, in
addition to intra-ventricular IFN-α, in two children age 12
and 13 years old who had had SSPE for approximately
eight months [38]. Some clinical improvement was noted
in both after several months on the therapy. Mixed success
with IVIG [39], amantadine [40], corticosteroids [40], and
acyclovir [40] have been reported in case series.
The cases we present demonstrate the controversies in
management. The child who received no active antiviral
or immune modulating treatment has survived for seven
years whereas the two children treated with a more stand-
ard regimen of isoprinosine and IFN died quickly. Further
high quality randomized trials are needed to evaluate IFN
and even though isoprinosine appears to be an effective
agent in SSPE, this too should be subject to a randomized
trial. Ongoing trials are feasible given the number of SSPE
cases in countries with endemic measles infection.
Although the profound deterioration of all children with
this condition makes it difficult to limit therapy, it is
important for the patient, physician and the health care
system to have proper data validating treatment decisions.
When available, pediatric palliative care services should
be accessed early in the course of SSPE.
Limitations
The use of active surveillance to document cases of disease
is limited by the interest and responses of the involved
pediatricians and pediatric neurologists. However, with a
response rate of 82–86%, this does not appear to be a con-
cern. Furthermore, with its dramatic clinical course, SSPE
is a disease that would almost certainly be referred for
pediatric neurology consultation, be managed at least at
some point in a tertiary referral centre, and its rarity would
generate considerable interest, all of these factors making
reporting more likely. The fact that initial report forms are
sent out monthly, with quarterly follow-up, and the
request that even negative responses are sent in, means
that it is unlikely that cases were missed.BMC Pediatrics 2005, 5:47 http://www.biomedcentral.com/1471-2431/5/47
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Conclusion
The cases reported here demonstrate the typical clinical
patterns of SSPE that physicians in Canada may encoun-
ter. This report should raise awareness of the disease and
will serve to re-familiarize them with the possibility of this
disorder arising in the context of normal exposures to
measles virus that Canadian children experience. Unfortu-
nately, little appears to change the usual dramatic neuro-
logical deterioration over time.
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